Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 7Pheochromocytoma 4Paraganglioma 4Adrenocortical Carcinoma 4Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Adenocarcinoma, Follicular 3Neoplasm Metastasis 2Adenoma, Islet Cell 2Vulvar Neoplasms 1Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Small Cell Lung Carcinoma 1Seminoma 1Rare Diseases 1Pseudomyxoma Peritonei 1Prostatic Neoplasms 1Perivascular Epithelioid Cell Neoplasms 1Parathyroid Neoplasms 1Paranasal Sinus Neoplasms 1Pancreatic Neoplasms 1Paget Disease, Extramammary 1Non functioning pancreatic endocrine tumor 1Neurofibrosarcoma 1Nasopharyngeal Carcinoma 1Multiple Sclerosis 1Mouth Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Melanoma 1

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Digestive System Neuroendocrine Tumor G1 × Specimen Handling × Endocrine × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡